Here are the latest stories being discussed in biopharma today:

1. Joshua Boger, founder of Vertex Pharmaceuticals, advises biotech leaders to anticipate market volatility instead of attempting to predict an end to market downturns. Currently serving as executive chairman for Alkeus Pharmaceuticals, Boger emphasizes the influence of changing market conditions on Vertex’s financial strategies and the importance of being adaptable and responsive.

2. Ex-Celgene chief, Mark Alles, is the new CEO of TORL Biotherapeutics, an antibody maker. Alles had been chairing the board at TORL and his new position is his first since selling Celgene to Bristol Myers Squibb for $74 billion in 2019. Former Goldfinch Bio CEO, Tony Johnson, replaces Pascal Neuville at GPCR biotech Domain Therapeutics.

3. Broad Institute co-founder, Stuart Schreiber, is spearheading a new biomedical research institute, Arena BioWorks, backed by $500 million funding from a group of billionaires. As well as conducting new research initiatives, the institute plans to create for-profit biotech companies under one roof and promises a faster translational research model.

4. UnitedHealth Group saw shares tumble 3% due to unexpected rising medical costs in the fourth quarter, despite strong overall annual revenue growth of 15%, equivalent to $371.6 billion.

5. Shanghai-based biopharma, Ji Xing, has acquired Biogen’s experimental therapy for acute ischemic stroke. Financial details were not disclosed.

6. The partnership between the Swedish biotech BioInvent and Exelixis has come to an end, with BioInvent regaining the rights to its immuno-oncology targets after Exelixis’ announced a restructuring.

7. ClinChoice, a Contract Research Organization (CRO), has bought Singapore-based CRO, CSI Medical Research, expanding its services into Southeast Asia, Australia, and New Zealand.